The effects of ld-IL-2 on the Treg populations (both adoptively transferred and endogenous) in the 9 patients of the TILT trial were compared with those of 9 Treg-T1D study that had received a comparable or higher Treg dosage in the original phase I trial (NCT01210664-Treg-T1D trial) (Figure 3A legend table and Supplemental Table 1). The gene discussed is IL2; the disease is type 1 diabetes mellitus.